

Telix Pharmaceuticals and RefleXion Medical Enter Strategic Collaboration for Treatment of High-Risk Cancers

Melbourne (Australia) – 8th July 2020. Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announced it has entered into a strategic collaboration agreement with Hayward, USA based [RefleXion Medical](#), a therapeutic oncology company pioneering biology-guided radiotherapy¹ (BgRT) as a new modality for treating all stages of cancer, to investigate the clinical utility of combining the companies’ technologies to improve treatment for high-risk or recurrent prostate and aggressive kidney cancers.

Under the agreement, the parties will evaluate several new positron emission tomography (PET) tracers, including ⁶⁸Ga-PSMA-11 for prostate cancer and ⁸⁹Zr-Girentuximab for kidney cancer², to evaluate their potential in guiding BgRT to treat disease.

“The Telix tracers show considerable potential for detecting metastatic disease,” said Phuoc Tran, M.D., Ph.D., professor of radiation oncology and molecular radiation sciences, oncology and urology at the Johns Hopkins School of Medicine in Baltimore, MD (U.S.A). “Combining them with RefleXion’s BgRT, which is designed to treat metastatic disease, could bring us a step closer to improving outcomes for these cancer types.”

BgRT uses biological emissions from a patient’s cancer cells created by injecting a small amount of a targeting molecule carrying a positron-emitting radioisotope known as a PET tracer, to guide external-beam radiotherapy (EBRT). As the PET tracer binds to the tumour cells, it produces emissions that signal the cancer’s location. The [RefleXion™ X1 machine](#) detects these emissions using PET detectors and responds in real time to direct BgRT to each tumour and destroy it, even in moving tumours. The most commonly used PET tracer is ¹⁸F-fluorodeoxyglucose (FDG), which can detect many different cancer types. However, its performance in certain tumour types and organs remains limited, particularly for kidney and prostate cancers. Telix’s new PET tracers are designed to target specific cancer types and are expected to be more accurate in this clinical setting.

“Telix’s cancer-specific PET tracers may provide a more complete and robust signal to guide BgRT for difficult-to-treat cancers of the prostate and kidney,” said Thorsten Melcher, Ph.D., chief business officer at RefleXion. “This collaboration is an important step in providing proof-of-concept that PET-based tumour emissions can guide our BgRT using different tracers and in different cancer types.”

Prostate specific membrane antigen (PSMA) imaging with ⁶⁸Ga-PSMA-11 is suited for imaging high-risk or recurrent prostate cancer due to its ability to detect the spread of cancer outside the prostate bed. PSMA imaging is emerging as a potential new standard of care for detecting and staging prostate cancer, subject to approval by regulators.³ For renal cancer applications, Telix’s ⁸⁹Zr-Girentuximab, the first zirconium-labelled PET tracer in late-stage clinical development, targets carbonic anhydrase IX (CA9), an antigen that may differentiate renal cancer, including metastases, from benign disease.

“The use of Telix’s cancer-specific PET tracers may enable us to guide RefleXion’s BgRT in patients with more advanced forms of prostate and kidney cancer,” said Christian Behrenbruch, Ph.D., CEO

¹ The RefleXion X1 BgRT capability requires 510(k) clearance; this feature is not available for sale.

² ⁶⁸Ga-PSMA-11 and ⁸⁹Zr-Girentuximab are available for investigational use under an FDA Investigational New Drug (IND) application. Neither imaging agent has a marketing authorization in any jurisdiction.

³ Trabulsi EJ, et al. Optimum Imaging Strategies for Advanced Prostate Cancer; ASCO Guideline. J Clin Oncol 38: 1963 – 1996 (published online January 15, 2020).

at Telix. “This collaboration also allows us to leverage the investment we’ve made in these tracers by expanding both their indications and overall procedure volumes.”

About Telix Pharmaceuticals Limited

Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne with international operations in Belgium, Japan and the United States. Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical needs in prostate, kidney and brain cancer. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com.

Telix Corporate Contact

Dr Christian Behrenbruch
Telix Pharmaceuticals Limited
CEO
Email: chris@telixpharma.com

Telix Investor Relations

Dr David N. Cade
Telix Pharmaceuticals Limited
CBO and Head of Investor Relations
Email: david.cade@telixpharma.com

Important Information

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the “U.S. Securities Act”), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the U.S. Securities Act or an exemption from the registration requirements of the U.S. Securities Act is available. None of the technologies or products described in this document have received a marketing authorisation in any jurisdiction. This announcement has been authorised for release by Dr Christian Behrenbruch, Managing Director and Chief Executive Officer.